Gonorrhea - Drug Pipeline Landscape, 2023
Description
Gonorrhea - Drug Pipeline Landscape, 2023
Gonorrhea is a sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae. Gonorrhea most often affects the urethra, rectum or throat. In females, gonorrhea can also infect the cervix.
Symptoms of Gonorrhea infection in men include painful urination, pain or swelling in one testicle and in women include increased vaginal discharge, painful urination, vaginal bleeding between periods and abdominal or pelvic pain.
Diagnosis of Gonorrhea can be done after analyzing a sample of cells. Samples can be collected by urine test or swab of affected area.
Treatment for Gonorrhea include one-time intramuscular injection of the antibiotic ceftriaxone.
Some companies that are active in the development of gonorrhea drugs include Evofem Inc., GlaxoSmithKline, and Entasis Therapeutics.
There are several clinical trials currently ongoing in gonorrhea drug development. The most promising trials are testing new antibiotics against gonorrhea bacteria. These new antibiotics are designed to be more effective against gonorrhea bacteria than existing antibiotics. Other ongoing trials are testing vaccine candidates against gonorrhea. These vaccines are designed to prevent gonorrhea infections by inducing an immune response against the bacteria.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Gonorrhea treatment such as EVO100, Gepotidacin, Zoliflodacin and others. Key players involved in the development of therapies to treat Gonorrhea are Alopexx Pharmaceuticals Inc, Biolytics Pharma, Entasis Therapeutics, Evofem Inc, GlaxoSmithKline and others. Three drugs are under late-stage Phase III clinical trials and some other drugs are under preclinical and discovery stages of development.
Report Highlights
Global Insight Service's, Gonorrhea - Drug Pipeline Landscape, 2023 report provides an overview of the Gonorrhea pipeline drugs. This report covers detailed insights on Gonorrhea drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Gonorrhea pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Gonorrhea is a sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae. Gonorrhea most often affects the urethra, rectum or throat. In females, gonorrhea can also infect the cervix.
Symptoms of Gonorrhea infection in men include painful urination, pain or swelling in one testicle and in women include increased vaginal discharge, painful urination, vaginal bleeding between periods and abdominal or pelvic pain.
Diagnosis of Gonorrhea can be done after analyzing a sample of cells. Samples can be collected by urine test or swab of affected area.
Treatment for Gonorrhea include one-time intramuscular injection of the antibiotic ceftriaxone.
Some companies that are active in the development of gonorrhea drugs include Evofem Inc., GlaxoSmithKline, and Entasis Therapeutics.
There are several clinical trials currently ongoing in gonorrhea drug development. The most promising trials are testing new antibiotics against gonorrhea bacteria. These new antibiotics are designed to be more effective against gonorrhea bacteria than existing antibiotics. Other ongoing trials are testing vaccine candidates against gonorrhea. These vaccines are designed to prevent gonorrhea infections by inducing an immune response against the bacteria.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Gonorrhea treatment such as EVO100, Gepotidacin, Zoliflodacin and others. Key players involved in the development of therapies to treat Gonorrhea are Alopexx Pharmaceuticals Inc, Biolytics Pharma, Entasis Therapeutics, Evofem Inc, GlaxoSmithKline and others. Three drugs are under late-stage Phase III clinical trials and some other drugs are under preclinical and discovery stages of development.
Report Highlights
Global Insight Service's, Gonorrhea - Drug Pipeline Landscape, 2023 report provides an overview of the Gonorrhea pipeline drugs. This report covers detailed insights on Gonorrhea drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Gonorrhea pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
71 Pages
- 1. Introduction
- 1.1 Gonorrhea - Pipeline Drugs, 2023 - Coverage
- 2. Disease Overview - Gonorrhea
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Gonorrhea - Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Clinical Stage Drugs-Phase III
- 5.1.1 EVO100
- 5.1.2 Gepotidacin
- 5.1.3 Zoliflodacin
- 5.2 Early Stage Drugs-Preclinical
- 5.2.1 Debio1453
- 5.2.2 F598
- 5.2.3 GneX12
- 5.2.4 PBP-539
- 5.2.5 SMT 571
- 5.3 Early Stage Drugs-Discovery
- 5.3.1 Gonorrhea Antibiotic
- 5.3.2 Gonorrhea Project
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 Alopexx Pharmaceuticals Inc
- 9.2 Biolytics Pharma
- 9.3 Debiopharm International SA.
- 9.4 Entasis Therapeutics
- 9.5 Evofem Inc
- 9.6 GlaxoSmithKline
- 9.7 Microbiotix Inc
- 9.8 Summit Therapeutics
- 9.9 TherapyX
- 9.10 VenatoRx Pharmaceuticals
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1.1 Number of Products under Development by Gonorrhea
- Table 1.2 Number of Products under Development by Companies
- Table 1.3 Products under Development by Companies
- Table 1.4 Products by Targets
- Table 1.5 Products by Mechanism of Action
- Table 1.6 Products by Molecule Type
- Table 1.7 Products by Route of Administration
- Table 2.1 Clinical Trial Details - EVO100/ Evofem Inc.
- Table 2.2 Clinical Trial Details - Gepotidacin/GlaxoSmithKline
- Table 3.1 Regulatory Designations
- Table 4.1 Inactive Drugs
- Table 4.2 Discontinued Drugs
- List of Figures
- Figure 1.1 Number of Products under Development for Gonorrhea, 2023
- Figure 1.2 Products by Top 5 Targets and Stage of Development for Gonorrhea, 2023
- Figure 1.3 Products by Top 5 Mechanism of Action and Stage of Development for Gonorrhea, 2023
- Figure 1.4 Products by Top 5 Molecule Type and Stage of Development for Gonorrhea, 2023
- Figure 1.5 Products by Top 5 Route of Administration and Stage of Development for Gonorrhea, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
